Clinical Trial: Phase 2b Open-label Study of Inaxaplin in Participants With Proteinuric APOL1 Mediated Kidney Disease

U.S., Jan. 28 -- ClinicalTrials.gov registry received information related to the study (NCT06794996) titled 'Phase 2b Open-label Study of Inaxaplin in Participants With Proteinuric APOL1 Mediated Kidney Disease' on Jan. 23.

Brief Summary: The purpose of the study is to evaluate the efficacy, safety, and tolerability of Inaxaplin (IXP) in participants with proteinuric APOL1- mediated kidney disease (AMKD).

Study Start Date: Feb. 06

Study Type: INTERVENTIONAL

Condition: Proteinuric Kidney Disease

Intervention: DRUG: Inaxaplin

Tablets for Oral Administration.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Vertex Pharmaceuticals Incorporated

Disclaimer: Curated by HT Syndication....